Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial

Affiliations

• ¹ Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
• ² Department of Lymphoma and Myeloma, Institute of Hematology and Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China.
• ³ Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Zhejiang, China.
• ⁴ Department of Medical Oncology, Jiangsu Institute of Cancer Research, Jiangsu Red Cross Cancer Center, Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, China.
• ⁵ Department of Oncology, Shanghai Dongfang Hospital, Tongji University, Shanghai, China.
• ⁶ Department of Lymphoma, Guangdong Academy of Science, Guangdong Provincial Peoples Hospital, Guangdong, China.
• ⁷ Department of Hematology, Beijing Hospital, Beijing, China.
• ⁸ JW Therapeutics (Shanghai) Co. Ltd., Shanghai, China.